文献速递消化系统肿瘤

转移性结直肠癌抗EGFR治疗的实施:挑战与未来展望

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
PubMed 文献 · Ann Oncol · 2020-01-01

本文综述抗EGFR单抗(西妥昔单抗或帕尼单抗)联合化疗用于RAS和BRAF野生型转移性结直肠癌的挑战与前景,并总结CAPRI-GOIM转化研究项目在分子选择、化疗强化、联合免疫检查点抑制剂及再挑战策略等方面的发现。

要点

  • 抗EGFR单抗联合化疗是RAS和BRAF野生型mCRC的有效治疗选择。
  • 提高抗EGFR疗效的策略包括分子选择、化疗强化、联合免疫检查点抑制剂及再挑战。
  • CAPRI-GOIM研究评估持续EGFR抑制的获益亚组及液体活检与组织检测的一致性。

核心结论

  • 抗EGFR单抗联合化疗是RAS和BRAF野生型mCRC的有效治疗选择。
  • 提高抗EGFR治疗疗效的新方法包括更好的分子选择、化疗强化、联合免疫检查点抑制剂及再挑战。
  • CAPRI-GOIM转化研究旨在确定可从持续EGFR抑制中获益的亚组并探索耐药机制。

研究设计与样本

  • 综述类文章,总结CAPRI-GOIM研究项目的转化和临床发现。
  • CAPRI-GOIM研究在KRAS野生型结直肠癌患者中开展广泛转化研究。

主要发现

  • 抗EGFR单抗如西妥昔单抗或帕尼单抗联合化疗对RAS和BRAF野生型mCRC患者有效。
  • 再挑战策略可用于既往对抗EGFR单抗治疗有反应的选择性患者。
  • CAPRI-GOIM研究评估液体活检与组织分子检测的一致性并探究抗EGFR治疗的新型潜在耐药机制。

临床怎么用

  • 对RAS和BRAF野生型mCRC患者可考虑抗EGFR单抗联合化疗。
  • 可对既往抗EGFR治疗有反应的选择性患者考虑EGFR阻断再挑战。
  • 分子选择有助于识别EGFR依赖性mCRC以优化抗EGFR治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment options for patients with RAS and BRAF wild-type mCRC. Nevertheless, several issues are still open concerning the optimal use of anti-EGFR drugs in the continuum of care of mCRC. Novel approaches for increasing the efficacy of anti-EGFR therapies include better molecular selection of EGFR-dependent mCRC, intensification of chemotherapy, combination of anti-EGFR MoAbs and immune checkpoint inhibitors, and reintroduction of EGFR blockade or 'rechallenge' in selected patients who have previously responded to anti-EGFR MoAb therapy. An extensive translational research program was conducted in the Cetuximab After Progression in KRAS wIld-type colorectal cancer patients-Gruppo Oncologico dell' Italia Meridionale (CAPRI-GOIM) study with the aims of determining which subgroups of patients could benefit from the continuous inhibition of EGFR, from evaluating the role of liquid biopsy-based and its concordance with tissue-based molecular testing, and from investigating novel potential mechanisms of resistance to anti-EGFR therapies. In this review, we summarize the translational and clinical findings of the CAPRI-GOIM program in the context of the current knowledge of therapeutic strategies and of ongoing research on more appropriate uses of anti-EGFR therapies in RAS and BRAF wild-type mCRC patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol. 2020. PMID: 31912793. doi:10.1016/j.annonc.2019.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。